How mutations affect the blood-brain barrier in brain tumors
Regulation of Angpt1 and DIPG blood-brain barrier integrity by H3K27M mutations
This study is looking at how certain changes in brain tumors, like DIPG and high-grade gliomas, affect the blood-brain barrier, with the hope of finding better ways to deliver treatments to these tough-to-treat tumors, which could help patients get more effective therapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Cincinnati NIH-funded |
| Lab location | 1 site (Cincinnati, United States) |
| Project ID | NIH-10984495 on NIH RePORTER |
What this research studies
This research investigates how specific mutations in brain tumors, particularly in diffuse intrinsic pontine glioma (DIPG) and high-grade gliomas, influence the integrity of the blood-brain barrier (BBB). By using advanced genomic profiling and mouse models, the study aims to understand the role of Angiopoietin 1 (Angpt1) in regulating BBB function. The goal is to uncover mechanisms that could improve drug delivery to brain tumors, which are often resistant to treatment due to the protective nature of the BBB. Patients may benefit from insights that could lead to more effective therapies targeting these tumors.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with high-grade gliomas, including pediatric and adult patients.
Not a fit: Patients with brain tumors that do not exhibit the specific mutations being studied may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for patients with brain tumors by enhancing drug delivery across the blood-brain barrier.
How similar studies have performed: Other research has shown promise in understanding blood-brain barrier dynamics in brain tumors, making this approach both relevant and potentially impactful.
Where this research is happening
Cincinnati, United States
- University of Cincinnati — Cincinnati, United States (Active)
Researchers
- Principal investigator: Phoenix, Timothy N — University of Cincinnati
- Study coordinator: Phoenix, Timothy N
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.